Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man
Eleanor Barnes(Oxford Health NHS Foundation Trust), Paul Klenerman(John Radcliffe Hospital), Anthony Brown(University of Oxford), Christian B. Willberg(University of Oxford), Rachel Townsend(University of Oxford), Loredana Siani(Sigma Tau (Italy)), Joel N. Meyer(Duke University), Mariarosaria Naddeo(Sigma Tau (Italy)), Richard Antrobus(University of Oxford), Alfredo Nicosia(Ceinge Biotecnologie Avanzate (Italy)), Ayako Kurioka(University of Oxford), Stefano Colloca(Sigma Tau (Italy)), Geraldine O’Hara(University of Oxford), Adrian V. S. Hill(University of Oxford), Virginia Ammendola(Sigma Tau (Italy)), Fabiana Grazioli(Ceinge Biotecnologie Avanzate (Italy)), Antonella Folgori(Sigma Tau (Italy)), Stefania Capone(Sigma Tau (Italy)), Leo Swadling(The London College), Stephen Aston(University of Oxford), Cinzia Traboni(Sigma Tau (Italy)), R. Huddart(University of Oxford), Kira Smith(University of Oxford), Abby Harrison(University of Oxford), Maria Luisa Esposito(Ceinge Biotecnologie Avanzate (Italy)), David Adams(University of Birmingham), Riccardo Cortese(Sigma Tau (Italy)), Ye Htun Oo(University Hospitals Birmingham NHS Foundation Trust)
Cited by 401
Related Papers
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
|The Lancet|2020|2.6k
Global distribution and prevalence of hepatitis C virus genotypes
|Hepatology|2014|1.6k
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
|Nature Medicine|2002|1.6k